Abstract
Beta-blocker–induced benefit in heart failure is under intense evaluation. Several large-scale mortality trials are currently being performed, with CIBIS II evaluating bisoprolol. The economic impact of beta-blocker therapy in heart failure has not been previously determined. The present study is a cost-effectiveness evaluation of bisoprolol treatment based on CIBIS I data. It considers direct costs, that is, the bisoprolol medication cost and the cost of hospitalization related to heart failure and its complications. Hospitalization costs were calculated from the French system of classification (PMSI), which provides costs according to homogeneous groups of patients (GHM). The cost difference between bisoprolol and placebo in the entire CIBIS population and the trial duration result from an increase in cost caused by bisoprolol treatment (+ 2018 Frs/patient) and a decrease in cost related to reduced hospitalization (6349 Frs/patient). A total savings per patient of about 4330 Frs was produced by bisoprolol. Cost reduction is still more pronounced in patients not having a history of myocardial infarction. We conclude that heart failure therapy with bisoprolol lowers medical healthcare costs, mainly due to the reduced rate of hospital admissions for heart failure.
Similar content being viewed by others
References
McMurray J, Davie A. The pharmacoeconomics of ACE inhibitors in chronic heart failure. Pharmacoeconomics 1996; 9:188-197.
Launois R, Launois B, Reboul-Marty J, Battais J, Lefebre P. Le coût de la sévérité de la maladie: Le cas de l'insuffisance cardiaque. J Econ Med 1990;8:395-412.
Waagstein F, Caidahl K, Wallentin I, Bergh Ch, Hjalmarson A. Long-term beta-blockade in dilated cardiomyopathy: Effects of short-and long-term metoprolol treatment followed by withdrawal and re-administration of metoprolol. Circulation 1989;80:551-563.
Swedberg K, Hjalmarson A, Waagstein F, Wallentin I. Beneficial effects of long-term beta-blockade withdrawal in patients with congestive cardiomyopathy. Br Heart J 1980; 44:117-133.
Waagstein F, Bristow MR, Swedberg K, et al. for the Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993;342:1441-1446.
Lechat P. Beta-blockade treatment in heart failure: The Cardiac Insufficiency Bisoprolol Study (CIBIS) project. J Cardiovasc Pharmacol 1990;16:158-163.
CIBIS Investigators and Committees. A randomised trial of beta-blockade in heart failure, the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994;90:1765-1773.
CIBIS II Scientific Committee. Design of the Cardiac Insuffi ciency Bisoprolol Study II (CIBIS II). Fund Clin Pharmacol 1997;11:138-142.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Levy, P., Lechat, P., Leizorovicz, A. et al. A Cost-Minimization of Heart Failure Therapy with Bisoprolol in the French Setting: An Analysis from CIBIS Trial Data. Cardiovasc Drugs Ther 12, 301–305 (1998). https://doi.org/10.1023/A:1007773901631
Issue Date:
DOI: https://doi.org/10.1023/A:1007773901631